Abstract 655P
Background
ADCs are a rapidly emerging modality of systemic anti-cancer treatment with 11 agents FDA approved and more under investigation.
Methods
Patients that received at least 1 dose of ADC in phase 1-3 trials at SCRI UK between 2012-2023 were included. Patient and tumor characteristics, toxicity and outcomes overall and for subgroups of interest were assessed using descriptive statistics and cox regression.
Results
102 patients from 16 trials (8 phase 1, 8 phase 2-3) of 13 different ADCs were included (median age 62 (32-81), male 32.4%). Main tumor types were breast (n=40, 38.5%) and gynecological (n=19, 18.3%). Median number of prior treatment lines was 3 (1-18). Payloads comprised alkylating agents (AA, n=3), microtubule inhibitors (MTI, n=8) or a topoisomerase inhibitor (Topo-I, n=2). 3 ADCs targeted an oncogene (HER2) vs tumor associated antigens (TAA). TRAEs of any grade occurred in 88% of patients (grade 3-4 25%). Colitis occurred in 3.8% (2.9%), ILD 3.8% (1.0%), neuropathy 26.0% (0%), eye toxicity 22.1% (0%) and hepatotoxicity 27.8% (4.8%). Most toxicities occurred early (
Conclusions
ADC activity is seen across different tumors with higher efficacy when oncogene targeted. Identification of timelines of expected toxicities is critical for clinical management and mitigation strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Woodford, A. Cammarota, K. Joshi, R.M. Grochot: Financial Interests, Institutional, Full or part-time Employment: HCA International. A. Williams: Financial Interests, Institutional, Full or part-time Employment: HCA International; Financial Interests, Personal, Advisory Role: Ellipses Pharma UK. E. Fontana: Financial Interests, Personal, Invited Speaker: Caris Life Science, Repair Therapeutics; Financial Interests, Personal, Other, Conference attendance: Sapience Pharma; Financial Interests, Personal, Invited Speaker, Conference Attendance: Bicycles Therapeutics; Financial Interests, Personal, Full or part-time Employment: Hospital Corporation of America (HCA) International; Financial Interests, Personal, Officer: EORTC; Financial Interests, Institutional, Coordinating PI: Repair Therapeutics, Amgen, Taiho Pharmaceutical; Financial Interests, Institutional, Local PI: Bicycle Therapeutics, Artios Pharma, Seagen, Nurix Therapeutics, BioNTech SE, Relay Therapeutics, Pfizer, Roche, Daiichi Sankyo, Gilead Science, Basilea Pharmaceutica, Jiangsu Hengrui Medicine, Mereo Biopharma, Hutchmed, Merus, Crescendo Biologics, GSK plc, BeiGene, Turning Point Therapeutics, Sapience Pharma, Arcus Bioscience, Exelixis, Nerviano Medica, Elipsees, Deciphera, Ribon Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01